AbbVie Inc. $ABBV Stock Position Lowered by Alteri Wealth LLC

Alteri Wealth LLC trimmed its position in shares of AbbVie Inc. (NYSE:ABBV) by 21.7% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 5,526 shares of the company’s stock after selling 1,528 shares during the period. Alteri Wealth LLC’s holdings in AbbVie were worth $1,026,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of the business. TD Capital Management LLC raised its position in AbbVie by 82.9% during the first quarter. TD Capital Management LLC now owns 128 shares of the company’s stock valued at $27,000 after buying an additional 58 shares during the period. Marshall & Sullivan Inc. WA purchased a new position in AbbVie during the 2nd quarter valued at about $25,000. Spurstone Advisory Services LLC acquired a new position in shares of AbbVie in the 2nd quarter valued at about $28,000. Financial Gravity Companies Inc. purchased a new stake in shares of AbbVie in the second quarter worth approximately $36,000. Finally, Bear Mountain Capital Inc. boosted its holdings in shares of AbbVie by 480.6% during the second quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock worth $40,000 after purchasing an additional 173 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Price Performance

NYSE ABBV opened at $233.83 on Wednesday. AbbVie Inc. has a fifty-two week low of $163.81 and a fifty-two week high of $244.81. The stock’s 50-day moving average is $225.84 and its two-hundred day moving average is $204.57. The firm has a market cap of $413.27 billion, a P/E ratio of 111.35, a price-to-earnings-growth ratio of 1.42 and a beta of 0.50. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.74 and a quick ratio of 0.61.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.09. The company had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The firm’s revenue was up 9.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 3.0%. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio is 524.24%.

Analyst Upgrades and Downgrades

ABBV has been the topic of several research reports. Scotiabank initiated coverage on shares of AbbVie in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 price objective on the stock. Wells Fargo & Company boosted their price target on shares of AbbVie from $240.00 to $260.00 and gave the company an “overweight” rating in a report on Friday, September 12th. HSBC set a $225.00 price objective on AbbVie in a report on Thursday, October 2nd. Hsbc Global Res downgraded AbbVie from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 1st. Finally, BMO Capital Markets upped their target price on AbbVie from $215.00 to $240.00 and gave the stock an “outperform” rating in a research report on Friday, September 12th. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and an average price target of $240.14.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.